Effect of antidepressant drug desvenlafaxine on anxiety and plasma BDNF level in patients.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
- Registration Number
- CTRI/2021/11/038260
- Lead Sponsor
- Dr Chaitali Chindhalore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Drug naïve patients of either gender having age between 18 to 70 years with a clinical diagnosis of depressive episode as per ICD 10 (F 32)
2.Hamilton Scale of Rating Depression (HAM-D) score >20;
3.Baseline Hamilton Anxiety Rating Scale (HAM-A) score > 14
Exclusion Criteria
1.Subjects with other coexistent psychiatric disorders as described by ICD 10, (World Health Organization, 2008)
2.Subjects on antianxiety medication within washout period
3.Use of psychoactive substances except tobacco and caffein
4.Concurrent debilitating illnesses like chronic renal failure, malignancy, cirrhosis etc
5.Subjects on drugs which are known to interact with the study medications
6.History of allergy to study medication
7.Lactating and pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Change in Hamilton anxiety rating scale (HAMA) score <br/ ><br>2. Change in somatic symptom scale (SSS8) score <br/ ><br>3. Change in plasma BDNF levelTimepoint: At the end of 4 and 8 weeks
- Secondary Outcome Measures
Name Time Method Treatment emergent adverse eventsTimepoint: at the end of 4 week and 8 week